title: Nanoporous capsules of block co-polymers of [(MeO-PEG-NH)-b-(L-GluA)]-PCL for the controlled release of anticancer drugs for therapeutic applications.
abstract: Herein, new nanoporous capsules of the block co-polymers of MeO-PEG-NH-(L-GluA)10 and polycaprolactone (PCL) have been synthesized through a surfactant-free cost-effective self-assembled soft-templating approach for the controlled release of drugs and for therapeutic applications. The nanoporous polymer capsules are designed to be biocompatible and are capable of encapsulating anticancer drugs (e.g., doxorubicin hydrochloride (DOX) and imatinib mesylate (ITM)) with a high extent (∼279 and ∼480 ng μg(-1), respectively). We have developed a nanoformulation of porous MeO-PEG-NH-(L-GluA)10-PCL capsules with DOX and ITM. The porous polymer nanoformulations have been programmed in terms of the release of anticancer drugs with a desired dose to treat the leukemia (K562) and human carcinoma cells (HepG2) in vitro and show promising IC50 values with a very high mortality of cancer cells (up to ∼96.6%). Our nanoformulation arrests the cell divisions due to 'cellular scenescence' and kills the cancer cells specifically. The present findings could enrich the effectiveness of idiosyncratic nanoporous polymer capsules for use in various other nanomedicinal and biomedical applications, such as for killing cancer cells, immune therapy, and gene delivery.
authors.affiliation: School of Engineering Sciences and Technology, University of Hyderabad, Hyderabad-500046, India.
authors.forename: Chander
authors.initials: C
authors.lastname: Amgoth
authors.forename: Gangappa
authors.initials: G
authors.lastname: Dharmapuri
authors.forename: Arunasree M
authors.initials: AM
authors.lastname: Kalle
authors.forename: Pradip
authors.initials: P
authors.lastname: Paik
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002214:Capsules / Q000737:chemistry; D002470:Cell Survival / Q000187:drug effects; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000494:pharmacology; D051272:Glucose Transporter Type 1; D057809:HEK293 Cells; D006801:Humans; D000068877:Imatinib Mesylate / Q000494:pharmacology; D020014:K562 Cells; D058608:Nanopores; D009369:Neoplasms / Q000188:drug therapy*; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry*; D011108:Polymers / Q000138:chemical synthesis* / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D051272:Glucose Transporter Type 1; D011091:Polyesters; D011108:Polymers; C495677:SLC2A1 protein, human; C016240:polycaprolactone; D004317:Doxorubicin; D000068877:Imatinib Mesylate